Delcath Systems (DCTH)
(Delayed Data from NSDQ)
$8.01 USD
+0.14 (1.78%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.00 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.01 USD
+0.14 (1.78%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.00 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Zacks News
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Delcath Systems (DCTH) delivered earnings and revenue surprises of -41.18% and 55.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's What Could Help Delcath Systems (DCTH) Maintain Its Recent Price Strength
by Zacks Equity Research
Delcath Systems (DCTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Does Delcath Systems (DCTH) Have the Potential to Rally 197.87% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 197.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 201.72% Upside in Delcath Systems (DCTH): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 201.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What Makes Delcath Systems (DCTH) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Delcath Systems (DCTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Steris (STE) Matches Q4 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 0% and 3.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83%
by Zacks Equity Research
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 244.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 277.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Delcath Systems (DCTH) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Delcath Systems (DCTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Delcath Systems (DCTH) delivered earnings and revenue surprises of 28.36% and 12.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) Soars 9.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
DexCom (DXCM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of -11.11% and 0.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices Inc. (MASS) delivered earnings and revenue surprises of 12.12% and 16.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical, Inc. (NARI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 128.57% and 2.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical, Inc. (ISRG) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 7.58% and 1.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Dynatronics Corporation (DYNT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -125% and 11.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 50% and 3.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 3.92% and 8.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of -2.63% and 1.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Delcath Systems, Inc. (DCTH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 12.38% and 10.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Tops Q3 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 5.56% and 1.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Semler Scientific Inc. (SMLR) Q3 Earnings Beat Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 24.32% and 6.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare (ACHC) Q3 Earnings Lag Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of -2.50% and 1.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?